Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high5.2500 29/09/15
52 week low2.1700 19/01/16
52 week change -1.0000 (-22.73%)
4 week volume14,603,642 02/09/16

Media for (VRP)

Presenter: Jan-Anders Karlsson
28/07/2014

Latest NewsMore

Exercise of options

RNS Number: 0739L Verona Pharma PLC 28 September 2016 Verona Pharma plc ("Verona Pharma" or the "Company") Exercise of Options The Company announces that it has issued 166,667 new ordinary shares in the capital of the Company (the "New Shares") following an exercise of share options by an employee. Application has been made to the London Stock...

Appointment of CFO

Verona Pharma plc ("Verona Pharma" or the "Company") Appointment of CFO 26 September 2016, Cardiff ? Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces the appointment of Piers John Morgan as Chief Financial Officer with effect from 26 September 2016. Mr Morgan...

Half-year Report

Verona Pharma plc ("Verona Pharma" or the "Company") Interim results for the six months ended 30 June 2016 Significant clinical progress and strong balance sheet bodes well for future of RPL554 13 September 2016, Cardiff ? Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today a...

Appointment of Vikas Sinha as Non-Executive Director

Verona Pharma plc ("Verona Pharma" or the "Company") Appointment of Vikas Sinha as Non-Executive Director 12 September 2016, Cardiff ? Verona Pharma plc (AIM: VRP), a drug development company focused on first-in-class medicines to treat respiratory diseases, today announces the appointment of Vikas Sinha to the Board of Verona Pharma as a Non-Ex...

Data on RPL554 to be presented at ERS Congress

Verona Pharma plc ("Verona Pharma" or the "Company") New clinical data on RPL554 to be presented at the 2016 ERS International Congress Detailed data from Phase 2a ?add-on? trial as ?LATE-BREAKING abstract? 30 August 2016, Cardiff ? Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respirator...

Notice of Results

Verona Pharma plc ("Verona Pharma" or the "Company") Notice of Results 10 August 2016, Cardiff ? Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, expects to announce its interim results for the six months ended 30 June 2016 on Tuesday 13 September 2016. -Ends- For further informa...

Director Deals - Verona Pharma PLC (VRP)

Dr Jan-Anders Karlsson, Chief Executive Officer, bought 600,000 shares in the company on the 9th August 2016 at a price ...

Director Dealing

RNS Number: 7030G Verona Pharma PLC 09 August 2016 Verona Pharma plc 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Dr. Jan-Anders Karlsson 2 Reason for the notification a) Position/status Chief Executive Officer b) Initial notification/Amendment Initial notification 3 Details of the issuer, emission allowance...

Fundamental DataMore

EPS-0.73
Dividend yield0 %

Equity Research (VRP)

edison investment research
Verona Pharma plc
26/07/2016
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
hardman & co
Verona Pharma plc
20/06/2016
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
hardman & co
Verona Pharma plc
16/03/2016
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...

Latest discussion posts More

  • Re: major shareholders

    bit of info re new regulations regarding disclosure requirements esp re pdmr http://www.fca.org.uk/markets/ukla/regulatory-disclosures/mar-implementation summary info ...
    28-Sep-2016
    mol42
  • Re: major shareholders

    meant to note as well over c5m added by Directors and senior management - 600k we know s j-a k so senior management the remainder c4.5m prior to today's rns - albeit ...
    28-Sep-2016
    mol42
  • Re: major shareholders

    website updated The Company's issued share capital consists of 2,565,886,493 ordinary shares with a nominal value of 0.1p each ("Ordinary Shares"), each share having equal ...
    28-Sep-2016
    mol42

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.21%
ID:ISIN:BMG4209G132713%
GULF KEYSTONE13%
ID:ISIN:BMG4209G124413%
RENEURON11%

Codes & Symbols

ISINGB00B06GSH43
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP